Bristol-Myers earnings could double by end of decade, says Goldman Goldman believes Bristol-Myers earnings could double ty the end of the decade given by PD-1 contribution. The firm believes investors are underestimating PD-1 and that peak sales could reach $7B by 2025. The firm reiterates its Conviction Buy rating and raised its price target to $44 from $40.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Teva launches generic Baraclude in U.S. Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).